Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration Resistant Prostate Cancer 1

Interventions

pembrolizumab 73 Carboplatin 60 Cyclophosphamide 59 Nivolumab 52 Paclitaxel 47 Gemcitabine 44 Cisplatin 43 Dexamethasone 41 Radiotherapy 36 Rituximab 32 Capecitabine 32 Bevacizumab 29 Docetaxel 28 fludarabine 27 atezolizumab 26 Cytarabine 26 avelumab 24 venetoclax 23 Trastuzumab 23 Oxaliplatin 23 Lenalidomide 23 Cetuximab 23 Azacitidine 23 Ipilimumab 22 Fluorouracil 22 Temozolomide 21 130-nm albumin-bound paclitaxel 21 fludarabine phosphate 20 Filgrastim 20 Bortezomib 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Terminated × tildrakizumab × Clear all

NCT04458311 2024-04-25

ACTIon

Institute of Cancer Research, United Kingdom

Phase 1/2 Terminated

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡